Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2019-11-27 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Director's Dealing Classification · 100% confidence The document is a formal notification regarding transactions of company shares by managers and closely related parties, specifically citing the Danish Securities Trading Act, section 28a. This aligns perfectly with the definition of a Director's Dealing report, which covers insider trades and transactions by executives.
2019-11-27 English
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly lists the name of the executive (Rie Schultz Hansen), their position (Interim CSO), the nature of the transaction (Sale of shares), and the specific details of the trade (price, volume, date, and venue). This is a classic insider dealing report, which corresponds to the 'Director's Dealing' category.
2019-11-27 English
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific individual (Hanne Heidenheim Bak), their position (Board member), the issuer (Zealand Pharma A/S), and details of a share transaction (purchase of warrants). This is a classic insider dealing report, which corresponds to the 'Director's Dealing' category.
2019-11-27 English
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly lists the name of the individual (Hanne Heidenheim Bak), their position (Board member), the nature of the transaction (Sales of shares), and the details of the financial instrument. This is a classic insider trading disclosure, which falls under the 'Director's Dealing' category.
2019-11-27 English
Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program
Director's Dealing Classification · 100% confidence The document is a formal notification regarding transactions in company shares by managers and closely related parties, specifically in connection with an employee warrant program. This falls under the category of 'Director's Dealing' (DIRS), which covers insider trades and transactions by company executives and their related parties as required by securities regulations.
2019-11-27 English
Director's Dealing 2019
Director's Dealing Classification · 100% confidence The document text is explicitly titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." This template structure, focusing on details like 'Position/status', 'Nature of the transaction', 'Price(s) and volume(s)', and 'Date of the transaction' for individuals in managerial roles, directly corresponds to insider trading disclosure requirements, specifically Director's Dealing reports (like Form 3, 4, or 5 in the US context, or MAR disclosures in the EU context). Reviewing the definitions, 'Director's Dealing (Code: DIRS)' is defined as 'Report of personal share transactions by company directors and executives (insider trades)'. This is the most precise match for the content provided.
2019-11-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.